SMYD3 was significantly overexpressed in ESCA and LIHC patients (Wurmbach et al., 2007; Hu et al., 2010; Kim et al., 2010; Roessler et al., 2010; Su et al., 2011), whereas SMYD4 and SMYD5 were significantly overexpressed in GC patients (D’Errico et al., 2009; Wang et al., 2012; Table 1). Here, SMYD3 is linked to gastric cancer.